Literature DB >> 8158024

Human experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development.

M S Cohen1, J G Cannon, A E Jerse, L M Charniga, S F Isbey, L G Whicker.   

Abstract

Neisseria gonorrhoeae infection is limited to the human host. Experimental urethral infection in male volunteers was used to study different aspects of the infection. Urethral installation of a variety of gonococcal variants (10(4)-10(6)) led to infection in 27 subjects, who developed pyuria and shed bacteria in urine before urethritis developed 1-6 days after gonococcal inoculation. The incubation period was affected by the inoculation procedure and size of the inoculum. Subjects were treated with intramuscular ceftriaxone (250 mg) if urethritis developed or at 6 days after inoculation. Urine cultures became negative within several hours of therapy, and symptoms resolved within 1 day of therapy. Infected patients suffered no major complications. Experimental male urethral gonococcal infection provides a unique opportunity to understand the biology and immunology of gonococcal infection and is an efficient method to test gonococcal vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8158024     DOI: 10.1093/infdis/169.3.532

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  73 in total

Review 1.  Challenge of investigating biologically relevant functions of virulence factors in bacterial pathogens.

Authors:  R Moxon; C Tang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

2.  In vivo selection for Neisseria gonorrhoeae opacity protein expression in the absence of human carcinoembryonic antigen cell adhesion molecules.

Authors:  Amy N Simms; Ann E Jerse
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Deciphering the Function of New Gonococcal Vaccine Antigens Using Phenotypic Microarrays.

Authors:  Benjamin I Baarda; Sarah Emerson; Philip J Proteau; Aleksandra E Sikora
Journal:  J Bacteriol       Date:  2017-08-08       Impact factor: 3.490

4.  Azurin of pathogenic Neisseria spp. is involved in defense against hydrogen peroxide and survival within cervical epithelial cells.

Authors:  Hsing-Ju Wu; Kate L Seib; Jennifer L Edwards; Michael A Apicella; Alastair G McEwan; Michael P Jennings
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice.

Authors:  Gregory A Price; Heather P Masri; Aimee M Hollander; Michael W Russell; Cynthia Nau Cornelissen
Journal:  Vaccine       Date:  2007-08-06       Impact factor: 3.641

Review 6.  STD vaccines--an overview.

Authors:  C T Barbosa-Cesnik; A Gerbase; D Heymann
Journal:  Genitourin Med       Date:  1997-10

Review 7.  The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women.

Authors:  Jennifer L Edwards; Michael A Apicella
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Commensal Neisseria Kill Neisseria gonorrhoeae through a DNA-Dependent Mechanism.

Authors:  Won Jong Kim; Dustin Higashi; Maira Goytia; Maria A Rendón; Michelle Pilligua-Lucas; Matthew Bronnimann; Jeanine A McLean; Joseph Duncan; David Trees; Ann E Jerse; Magdalene So
Journal:  Cell Host Microbe       Date:  2019-08-01       Impact factor: 21.023

9.  Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses.

Authors:  Mathanraj Packiam; Sandra J Veit; Deborah J Anderson; Robin R Ingalls; Ann E Jerse
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

10.  Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection.

Authors:  B Feinen; A E Jerse; S L Gaffen; M W Russell
Journal:  Mucosal Immunol       Date:  2010-01-27       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.